|
1
|
Chen Q, Wang C, Chen G, Hu Q and Gu Z:
Delivery strategies for immune checkpoint blockade. Adv Healthc
Mater. 7(e1800424)2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Demaria O, Cornen S, Daeron M, Morel Y,
Medzhitov R and Vivier E: Harnessing innate immunity in cancer
therapy. Nature. 574:45–56. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kakimi K, Karasaki T, Matsushita H and
Sugie T: Advances in personalized cancer immunotherapy. Breast
Cancer. 24:16–24. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zhang YY and Zhang ZM: The history and
advances in cancer immunotherapy: Understanding the characteristics
of tumor-infiltrating immune cells and their therapeutic
implications. Cell Mol Immunol. 17:807–821. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Abbott M and Ustoyev Y: Cancer and the
immune system: The history and background of immunotherapy. Semin
Oncol Nurs. 35(150923)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chen Q, Chen MC and Liu Z: Local
biomaterials-assisted cancer immunotherapy to trigger systemic
antitumor responses. Chem Soc Rev. 48:5506–5526. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Murciano-Goroff YR, Warner AB and Wolchok
JD: The future of cancer immunotherapy: Microenvironment-targeting
combinations. Cell Res. 30:507–519. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tang S, Ning Q, Yang L, Mo Z and Tang S:
Mechanisms of immune escape in the cancer immune cycle. Int
Immunopharmacol. 86(106700)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Barbari C, Fontaine T, Parajuli P,
Lamichhane N, Jakubski S, Lamichhane P and Deshmukh RR:
Immunotherapies and combination strategies for immuno-oncology. Int
J Mol Sci. 21(5009)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kumar A, Swain CA and Shevde LA: Informing
the new developments and future of cancer immunotherapy future of
cancer immunotherapy. Cancer Metast Rev. 40:549–562.
2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Finn OJ: A believer's overview of cancer
immunosurveillance and immunotherapy. J Immunol. 200:385–391.
2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chen DS and Mellman I: Elements of cancer
immunity and the cancer-immune set point. Nature. 541:321–330.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Helmy KY, Patel SA, Nahas GR and Rameshwar
P: Cancer immunotherapy: Accomplishments to date and future
promise. Ther Deliv. 4:1307–1320. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sharma P, Hu-Lieskovan S, Wargo JA and
Ribas A: Primary, adaptive, and acquired resistance to cancer
immunotherapy. Cell. 168:707–723. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gubin MM and Vesely MD: Cancer
immunoediting in the era of immuno-oncology. Clin Cancer Res.
20:3917–3928. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kelly RJ: The emerging role of
immunotherapy for esophageal cancer. Curr Opin Gastroenterol.
35:337–343. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Gide TN, Quek C, Menzies AM, Tasker AT,
Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, et
al: Distinct immune cell populations define response to anti-PD-1
monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. Cancer
Cell. 35:238–255.e6. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hsu A, Mendelson L and Almhanna K: Immune
checkpoint inhibitors in the treatment of gastrointestinal
malignancies: A review of current and future therapies. R I Med J
(2013). 103:33–37. 2020.PubMed/NCBI
|
|
19
|
Chen K, Cheng G, Zhang F, Zhang N, Li D,
Jin J, Wu J, Ying L, Mao W and Su D: Prognostic significance of
programmed death-1 and programmed death-ligand 1 expression in
patients with esophageal squamous cell carcinoma. Oncotarget.
7:30772–30780. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chen L, Deng H, Lu M, Xu B, Wang Q, Jiang
J and Wu C: B7-H1 expression associates with tumor invasion and
predicts patient's survival in human esophageal cancer. Int J Clin
Exp Pathol. 7:6015–6023. 2014.PubMed/NCBI
|
|
21
|
Ostrand-Rosenberg S, Horn LA and Haile ST:
The programmed death-1 immune-suppressive pathway: Barrier to
antitumor immunity. J Immunol. 193:3835–3841. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Pham F and Dalle S: Safety of
pembrolizumab for resected stage III melanoma. Expert Opin Drug
Saf. 19:1221–1227. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T,
Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al: Safety and
efficacy of pembrolizumab monotherapy in patients with previously
treated advanced gastric and gastroesophageal junction cancer:
Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol.
4(e180013)2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Seiwert TY, Burtness B, Mehra R, Weiss J,
Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et
al: Safety and clinical activity of pembrolizumab for treatment of
recurrent or metastatic squamous cell carcinoma of the head and
neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial.
Lancet Oncol. 17:956–965. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kato R, Yamasaki M, Urakawa S, Nishida K,
Makino T, Morimoto-Okazawa A, Kawashima A, Iwahori K, Suzuki S,
Ueda R, et al: Increased Tim-3(+) T cells in PBMCs during nivolumab
therapy correlate with responses and prognosis of advanced
esophageal squamous cell carcinoma patients. Cancer Immunol
Immunother. 67:1673–1683. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhao Y, Yang W, Huang Y, Cui R, Li X and
Li B: Evolving roles for targeting CTLA-4 in cancer immunotherapy.
Cell Physiol Biochem. 47:721–734. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kojima T and Doi T: Immunotherapy for
esophageal squamous cell carcinoma. Curr Oncol Rep.
19(33)2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Saito T, Wada H, Yamasaki M, Miyata H,
Nishikawa H, Sato E, Kageyama S, Shiku H, Mori M and Doki Y: High
expression of MAGE-A4 and MHC class I antigens in tumor cells and
induction of MAGE-A4 immune responses are prognostic markers of
CHP-MAGE-A4 cancer vaccine. Vaccine. 32:5901–5907. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Iinuma H, Fukushima R, Inaba T, Tamura J,
Inoue T, Ogawa E, Horikawa M, Ikeda Y, Matsutani N, Takeda K, et
al: Phase I clinical study of multiple epitope peptide vaccine
combined with chemoradiation therapy in esophageal cancer patients.
J Transl Med. 12(84)2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kono K, Iinuma H, Akutsu Y, Tanaka H,
Hayashi N, Uchikado Y, Noguchi T, Fujii H, Okinaka K, Fukushima R,
et al: Multicenter, phase II clinical trial of cancer vaccination
for advanced esophageal cancer with three peptides derived from
novel cancer-testis antigens. J Transl Med. 10(141)2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kono K, Mizukami Y, Daigo Y, Takano A,
Masuda K, Yoshida K, Tsunoda T, Kawaguchi Y, Nakamura Y and Fujii
H: Vaccination with multiple peptides derived from novel
cancer-testis antigens can induce specific T-cell responses and
clinical responses in advanced esophageal cancer. Cancer Sci.
100:1502–1509. 2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Alsina M, Moehler M and Lorenzen S:
Immunotherapy of esophageal cancer: Current status, many trials and
innovative strategies. Oncol Res Treat. 41:266–271. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Toh U, Yamana H, Sueyoshi S, Tanaka T,
Niiya F, Katagiri K, Fujita H, Shirozou K and Itoh K: Locoregional
cellular immunotherapy for patients with advanced esophageal
cancer. Clin Cancer Res. 6:4663–4673. 2000.PubMed/NCBI
|
|
34
|
Kageyama S, Ikeda H, Miyahara Y, Imai N,
Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, et al:
Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced
lymphocytes in patients with recurrent esophageal cancer. Clin
Cancer Res. 21:2268–2277. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Schizas D, Charalampakis N, Kole C,
Mylonas KS, Katsaros I, Zhao M, Ajani JA, Psyrri A, Karamouzis MV
and Liakako T: Immunotherapy for esophageal cancer: A 2019 update.
Immunotherapy. 12:203–218. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ralph C, Elkord E, Burt DJ, O'Dwyer JF,
Austin EB, Stern PL, Hawkins RE and Thistlethwaite FC: Modulation
of lymphocyte regulation for cancer therapy: A phase II trial of
tremelimumab in advanced gastric and esophageal adenocarcinoma.
Clin Cancer Res. 16:1662–1672. 2010.PubMed/NCBI View Article : Google Scholar
|
|
37
|
De Mello RA, Lordick F, Muro K and
Janjigian YY: Current and future aspects of immunotherapy for
esophageal and gastric malignancies. Am Soc Clin Oncol Educ Book.
39:237–247. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Le DT, Bendell JC, Calvo E, Kim JW,
Ascierto PA, Ott PS, Bono P, Jaeger D, Evans TR, Braud FG, et al:
Safety and activity of nivolumab monotherapy in advanced and
metastatic (A/M) gastric or gastroesophageal junction cancer
(GC/GEC): Results from the CheckMate-032 study. J Clin Oncol.
34(79157577)2016.
|
|
39
|
Kang YK, Satoh T, Ryu MH, Chao Y, Kato K,
Chung HC, Chen JS, Muro K, Kang WK, Yoshikawa T, et al: Nivolumab
(ONO-4538/BMS-936558) as salvage treatment after second or
later-line chemotherapy for advanced gastric or gastroesophageal
junction cancer (AGC): A double-blinded, randomized, phase III
trial. J Clin Oncol 35: DOI:10.1200/JCO.2017.35.4_SUPPL.2,
2017.
|
|
40
|
de Guillebon E, Roussille P, Frouin E and
Tougeron D: Anti program death-1/anti program death-ligand 1 in
digestive cancers. World J Gastrointest Oncol. 7:95–101.
2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Cancer Genome Atlas Research Network.
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Fuchs CS, Ozguroglu M, Bang YJ, Di
Bartolomeo M, Mandala M, Ryu MH, Fornaro L, Olesinski T, Caglevic
C, Chung HC, et al: Pembrolizumab versus paclitaxel for previously
treated PD-L1-positive advanced gastric or gastroesophageal
junction cancer: 2-year update of the randomized phase 3
KEYNOTE-061 trial. Gastric Cancer. 25:197–206. 2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Shitara K, Van Cutsem E, Bang YJ, Fuchs C,
Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, et al:
Efficacy and safety of pembrolizumab or pembrolizumab plus
chemotherapy vs chemotherapy alone for patients with first-line,
advanced gastric cancer: The KEYNOTE-062 phase 3 randomized
clinical trial. JAMA Oncol. 6:1571–1580. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Kim ST, Cristescu R, Bass AJ, Kim KM,
Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, et al:
Comprehensive molecular characterization of clinical responses to
PD-1 inhibition in metastatic gastric cancer. Nat Med.
24:1449–1458. 2018.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Chen Y, Guo ZQ, Shi CM, Zhou ZF, Ye YB and
Chen Q: Efficacy of adjuvant chemotherapy combined with
immunotherapy with cytokine-induced killer cells for gastric cancer
after d2 gastrectomy. Int J Clin Exp Med. 8:7728–7736.
2015.PubMed/NCBI
|
|
46
|
Yoneda A, Kuroki T and Eguchi S:
Immunotherapeutic advances in gastric cancer. Surg Today.
51:1727–1735. 2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Masuzawa T, Fujiwara Y, Okada K, Nakamura
A, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Osawa
R, et al: Phase I/II study of S-1 plus cisplatin combined with
peptide vaccines for human vascular endothelial growth factor
receptor 1 and 2 in patients with advanced gastric cancer. Int J
Oncol. 41:1297–1304. 2012.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Ishikawa H, Imano M, Shiraishi O, Yasuda
A, Peng YF, Shinkai M, Yasuda T, Imamoto H and Shiozaki H: Phase I
clinical trial of vaccination with LY6K-derived peptide in patients
with advanced gastric cancer. Gastric. 17:173–180. 2014.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Zhang GQ, Zhao H, Wu JY, Li JY, Yan X,
Wang G, Wu LL, Zhang XG, Shao Y, Wang Y and Jiao SC: Prolonged
overall survival in gastric cancer patients after adoptive
immunotherapy. World J Gastroenterol. 21:2777–2785. 2015.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Song Y, Tong C, Wang Y, Gao Y, Dai H, Guo
Y, Zhao X, Wang Y, Wang Z, Han W and Chen L: Effective and
persistent antitumor activity of HER2-directed CAR-T cells against
gastric cancer cells in vitro and xenotransplanted tumors in vivo.
Protein Cell. 9:867–878. 2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Xie J, Fu L and Jin L: Immunotherapy of
gastric cancer: Past, future perspective and challenges. Pathol Res
Pract. 218(153322)2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Johdi NA and Sukor NF: Colorectal cancer
immunotherapy: Options and strategies. Front Immunol.
11(1624)2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Marcus L, Lemery SJ, Keegan P and Pazdur
R: FDA approval summary: Pembrolizumab for the treatment of
microsatellite instability-high solid tumors. Clin Cancer Res.
25:3753–3758. 2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Ardolino L and Joshua A: Immune checkpoint
inhibitors in malignancy. Aust Prescr. 42:62–67. 2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aguilar EA, Bardelli A, Benson A,
Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Anna Oncol.
27:1386–1422. 2016.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Eng
J Med. 372:2509–2520. 2015.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Leoni G, D'Alise AM, Cotugno G, Langone F,
Garzia I, De Lucia M, Fichera I, Vitale R, Bignone V, Tucci FG, et
al: A genetic vaccine encoding shared cancer neoantigens to treat
tumors with microsatellite instability. Cancer Res. 80:3972–3982.
2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Quiroga D, Lyerly HK and Morse MA:
Deficient mismatch repair and the role of immunotherapy in
metastatic colorectal cancer. Curr Treat Options Oncol.
17(41)2016.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Vermorken JB, Claessen AM, van Tinteren H,
Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E,
Ransom JH, et al: Active specific immunotherapy for stage II and
stage III human colon cancer: A randomised trial. Lancet.
353:345–350. 1999.PubMed/NCBI View Article : Google Scholar
|
|
60
|
de Weger VA, Turksma AW, Voorham QJ, Euler
Z, Bril H, van den Eertwegh AJ, Bloemena E, Pinedo HM, Vermorken
JB, van Tinteren H, et al: Clinical effects of adjuvant active
specific immunotherapy differ between patients with
microsatellite-stable and microsatellite-instable colon cancer.
Clin Cancer Res. 18:882–889. 2012.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Parkhurst MR, Yang JC, Langan RC, Dudley
ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry
RM, et al: T cells targeting carcinoembryonic antigen can mediate
regression of metastatic colorectal cancer but induce severe
transient colitis. Mol Ther. 19:620–626. 2011.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Pegram HJ, Park JH and Brentjens RJ: CD28z
CARs and armored CARs. Cancer J. 20:127–133. 2014.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Wang DK, Zuo Q, He QY and Li B: Targeted
immunotherapies in gastrointestinal cancer: From molecular
mechanisms to implications. Front Immunol.
12(705999)2021.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Casak SJ, Marcus L, Fashoyin-Aje L, Mushti
SL, Cheng J, Shen YL, Pierce WF, Her L, Goldberg KB, Theoret MR, et
al: FDA approval summary: Pembrolizumab for the first-line
treatment of patients with MSI-H/dMMR advanced unresectable or
metastatic colorectal carcinoma. Clin Cancer Res. 27:4680–4684.
2021.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Janjigian YY, Shitara K, Moehler M,
Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T,
Bragagnoli AC, et al: First-line nivolumab plus chemotherapy versus
chemotherapy alone for advanced gastric, gastro-oesophageal
junction, and oesophageal adenocarcinoma (CheckMate 649): A
randomised, open-label, phase 3 trial. Lancet. 398:27–40.
2021.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Saito M and Kono K: Landscape of
EBV-positive gastric cancer. Gastric Cancer. 24:983–989.
2021.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Li K, Zhang A, Li X, Zhang H and Zhao L:
Advances in clinical immunotherapy for gastric cancer. Biochim
Biophys Acta Rev Cancer. 1876(188615)2021.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Mitchell TC, Hamid O, Smith DC, Bauer TM,
Wasser JS, Olszanski AJ, Luke JJ, Balmanoukian AS, Schmidt EV, Zhao
Y, et al: Epacadostat plus pembrolizumab in patients with advanced
solid tumors: Phase I results from a multicenter, open-label phase
I/II Trial (ECHO-202/KEYNOTE-037). J Clin Oncol. 36:3223–3230.
2018.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Harpreet S, Christopher H, Jennifer M, et
al: A phase I study of a yeast-based therapeutic cancer vaccine,
GI-6301, targeting brachyury in patients with metastatic carcinoma.
J Clin Oncol. 32: 15_suppl(e14026-e14026)2014.
|
